Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial

Main Article Content

Michael Migden
Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX

Danny Rischin
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Medha Sasane
Sanofi, Bridgewater, NJ

Vera Mastey
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Anna Pavlick
Department of Medical Oncology, New York University Langone Medical Center, New York NY

Chrysalyne Schmults
Department of Dermatology, Brigham and Women?s Hospital, Harvard Medical School, Boston, MA

Zhen Chen
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Alexander Guminski
Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia

Axel Hauschild
Department of Dermatology, University Hospital (UKSH), Kiel, Germany

Denise Bury
Sanofi, Cambridge, MA

Anne Lynn Chang
Department of Dermatology, Stanford University School of Medicine, Rdwood City, CA

Guilherme Rabinowits
Department of Hematology/Oncology, Miami Cancer Institute/Baptist Health South Florida, Miami, FL

Sheriff Ibrahim
Department of Dermatology, Rochester Medical Center, Rochester, NY

Israel Lowy
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Matthew Fury
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Siyu Li
Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ

Chieh-I Chen
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Keywords

Skin Cancer, Squamous Cell Carcinoma, Biologic, PD-1 Inhibitor, Cemiplimab, Quality of Life

Abstract

Abstract not available.

References

1. Karia PS et al. J Am Acad Dermatol. 2013;68:957–966.

2. Rogers HW et al. JAMA Dermatol. 2015;151:1081–1086.

3. Que SK et al. JAAD. 2018;78:237–247.

4. Ahmed SR et al. Expert Rev Clin Pharmacol. 2019;12:947–951.

5. Migden MR et al. N Engl J Med. 2018;379:341–351.

6. Rischin D et al. Ann Oncol. 2019;30(suppl 5):536–537.

7. Migden MR et al. J Clin Oncol. 2019;37(15 suppl):6015.

8. Migden MR et al. Lancet Oncol. 2020;21:294–305.

9. Aaronson NK et al. J Natl Cancer Inst. 1993;85:365–376.

10. Mills KC et al. Arch Dermatol. 2012;148:1422–1423.

11. Osoba D et al. J Clin Oncol. 1998;16:139–144.

12. Scott NW et al. EORTC QLQ-C30 Reference Values. 2nd ed. Brussels, Belgium: EORTC Quality of Life Group. 2008. Available at: www.eortc.org/app/uploads/sites/2/2018/02/

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.122

Article Details

How to Cite
Migden, M., Rischin, D., Sasane, M., Mastey, V., Pavlick, A., Schmults, C., Chen, Z., Guminski, A., Hauschild, A., Bury, D., Chang, A. L., Rabinowits, G., Ibrahim, S., Lowy, I., Fury, M., Li, S., & Chen, C.-I. (2020). Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial. SKIN The Journal of Cutaneous Medicine, 4(6), s122. https://doi.org/10.25251/skin.4.supp.122
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4 > >>